Skip to main content.

Frequently Asked Questions

Looking for answers about the Masonic Cancer Alliance? Take a look at our most frequently asked questions (FAQs) to learn more.

What is the MCA?

The MCA is a membership-based organization that brings cancer research, care and support professionals together to advance the quality and reach of cancer prevention, early detection, treatment, and survivorship in the Heartland.

The MCA links The University of Kansas Cancer Center with hospitals, physicians, nurses and patients throughout Kansas and Western Missouri. The Alliance advances access to cutting-edge clinical trials as well as professional education, networking, and outreach opportunities.

View the questions below for more answers.

Hospitals and physician groups across Kansas and western Missouri are eligible to become MCA members. Three membership categories are currently offered: Community Partner, Clinical Research Partner and Partner Advisory Board Member.

Cancer support, advocacy, industry and government organization membership levels are in development. Please contact Hope Krebill, Executive Director, at or 913-588-3739 if your organization is interested in joining.

There are numerous benefits to joining the MCA for oncologists, primary care physicians, hospital administrators, and cancer care professionals.


  • Increased visibility and recognition as a center doing research
  • Greater patient retention which benefits market share growth
  • Enhanced ability to recruit and retain outstanding cancer physicians, nurses, and support staff
  • Access to network IRB and reduces administrative burden for clinical trials
  • Additional support and resources to enhance community outreach, marketing and public relations


  • Increased access to innovative clinical trials
  • Enhanced network of research and clinical oncologists
  • Increased access to consultative services and second opinions
  • Access to the latest evidence-based guidelines
  • Continuing medical education opportunities


  • Expanded network of cancer care professionals working together
  • Increased access to comprehensive cancer prevention, screening, diagnosis and care information and resources
  • The latest information on cancer care
  • Improved usage of regional cancer data
  • Increased opportunities to expand knowledge base
  • Continuing cancer care education opportunities
  • Advances comprehensive treatment locally
  • Offers multidisciplinary care for every diagnosis
  • Enables immediate state-of-the-art care to patients for whom standard therapy has failed
  • Improves access to cancer screening and prevention
  • Provides survivorship
  • Helps attract and retain top oncology-trained talent eager to provide advanced treatment in rural areas
  • Cancer Screenings
  • Support programs

A core principle of the Masonic Cancer Alliance is to facilitate advanced treatment for cancer patients as close to home as possible. In many cases, oncologists affiliated with MCA Clinical Research Partners will have access to cutting-edge clinical trials and treatment protocols at their location.

The MCA expects all member organizations to help support the collaborative nature of the program by contributing constructive ideas and feedback. Each member identifies a contact person for their institution. Dues must be paid by June 30th each year to remain a member in good standing. MCA Clinical Research Partners are expected to participate in and actively enroll for clinical trials.

Cancer doesn't stop at the state line and there are many residents in western Missouri that also will benefit from a relationship with the University of Kansas Cancer Center. In addition, including regional hospitals and oncology groups in the MCA broadens the expertise of the network and enhances collaboration.

Contact the Masonic Cancer Alliance Executive Director, Hope Krebill, at 913-588-3739 or A point person from the interested organization will need to be named to work with Ms. Krebill in the approval process. To become a member in good standing, the prospective organization must sign a contract and pay the respective annual dues.

A site visit must also be completed to assess the clinical trials infrastructure before the membership process is finalized for clinical research partners or Partners Advisory Board members.